80 completed. 80 Phase 2, 14 Phase 1, 10 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 80 | Completed 80 |
| Phase 1 | 14 | Completed 14 |
| Phase 3 | 10 | Completed 10 |
Follow Paralysis: new trials by email Literature Review of Paralysis trials Research Report on Paralysis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis. CIN-102 Dose 15mg, Placebo, CIN-102 Dose 10mg - Idiopathic Gastroparesis | Phase 2 | Completed | CinDome Pharma, Inc. | 416 | 2025-01-29 | 2026-07-13 |
| AMX0035 and Progressive Supranuclear Palsy AMX0035, Placebo - Progressive Supranuclear Palsy, PSP | Phase 2 / Phase 3 | Completed | Amylyx Pharmaceuticals Inc. | 139 | 2023-12-21 | 2026-04-30 |
| Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011 GV1001 Placebo, GV1001 1.12mg - Progressive Supranuclear Palsy | Phase 2 | Completed | GemVax & Kael | 67 | 2023-12-12 | 2025-11-21 |
| GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP) GV1001 Placebo, GV1001 0.56mg, GV1001 1.12mg - Progressive Supranuclear Palsy | Phase 2 | Completed | GemVax & Kael | 78 | 2023-06-14 | 2026-02-10 |
| Study Testing Benefits of Ursolic Acid (UA) as a Countermeasure To Myopenia and Insulin Resistance in Chronic Spinal Cord Injury (SCI) Ursolic Acid, Strength Training - Spinal Cord Injuries, Tetraplegia | Phase 2 | Completed | University of Miami | 10 | 2023-03-27 | 2025-05-21 |
| A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis CIN-102 Dose 15mg or 10mg, Placebo - Diabetic Gastroparesis | Phase 2 | Completed | CinDome Pharma, Inc. | 382 | 2023-03-27 | 2026-11-05 |
| Different Doses of Naronapride vs. Placebo in Gastroparesis Naronapride, Placebo - Gastroparesis | Phase 2 | Completed | Dr. Falk Pharma GmbH | 328 | 2023-01-03 | 2026-10-07 |
| Evaluating Neostigmine Effect on Reducing Gastric Residual Volume as Compared With Metoclopramide and Ondansetron Neostigmine, Ondansetron 8mg, Metoclopramide Injection - Delayed Gastric Emptying | Phase 2 | Completed | Tanta University | 90 | 2022-04-15 | 2022-10-20 |
| Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis PCS12852, Placebo - Gastroparesis | Phase 2 | Completed | Processa Pharmaceuticals | 25 | 2022-03-09 | 2026-10-22 |
| A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) TPN-101, 100 mg/day, TPN-101, 200 mg/day, TPN-101, 400 mg/day - Progressive Supranuclear Palsy | Phase 2 | Completed | Transposon Therapeutics, Inc. | 42 | 2021-12-12 | 2026-04-08 |
| The KHENEREXT Study Oral administration of 100 mg KH176 twice daily - Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation | Phase 2 | Completed | Khondrion BV | 11 | 2021-08-09 | 2024-03-06 |
| PET Imaging to Delineate Macrophage Activation in Diabetic Gastroparesis PET/CT Scan with 11C-ER176, Core biopsy of gastric muscle - Diabetes, Gastroparesis With Diabetes Mellitus | Phase 2 / Phase 3 | Completed | Mayo Clinic | 12 | 2021-05-10 | 2023-04-18 |
| A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP AZP2006 oral solution, Placebo oral solution - Progressive Supranuclear Palsy | Phase 2 | Completed | AlzProtect SAS | 36 | 2020-06-22 | 2025-03-17 |
| Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) NBMI, Placebo - Progressive Supranuclear Palsy, Multiple System Atrophy | Phase 2 | Completed | EmeraMed | 20 | 2019-09-16 | 2021-09-23 |
| Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia Cannabidiol, placebo - Gastroparesis, Dyspepsia | Phase 2 | Completed | Mayo Clinic | 92 | 2019-09-04 | 2024-02-13 |
| Buspirone for Early Satiety and Symptoms of Gastroparesis Buspirone, Placebo - Gastroparesis | Phase 2 | Completed | Johns Hopkins Bloomberg School of Public Health | 96 | 2019-08-27 | 2023-06-15 |
| NISCI - Nogo Inhibition in Spinal Cord Injury NG-101, Placebos - Spinal Cord Injury, Acute | Phase 2 | Completed | University of Zurich | 129 | 2019-05-15 | 2023-04-04 |
| A Study of CNSA-001 in Women With Diabetic Gastroparesis CNSA-001, Placebo - Gastroparesis | Phase 2 | Completed | PTC Therapeutics | 21 | 2019-02-27 | 2022-01-05 |
| A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG) TAK-906 Maleate, Metaclopramide, TAK-906 Maleate Placebo - Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis | Phase 2 | Completed | Millennium Pharmaceuticals, Inc. | 51 | 2017-09-26 | 2021-01-06 |
| Contralaterally Controlled Functional Electrical Stimulation Plus Video Games for Hand Therapy After Stroke Contralaterally Controlled Functional Electrical Stimulation (CCFES), Hand Therapy Video Games - Upper Extremity Hemiplegia, Stroke | Phase 2 | Completed | VA Office of Research and Development | 52 | 2017-06-19 | 2024-01-05 |
Showing 20 of 80. Sign in to see all of them.
Gastroparesis (35) · Supranuclear Palsy, Progressive (13) · Diabetes Mellitus (12) · Hemiplegia (12) · Stroke (12) · Quadriplegia (10) · Spinal Cord Injuries (10) · Paraplegia (7) · Vomiting (5) · Nausea (4) · Paresis (3) · Vocal Cord Paralysis (3) · Abdominal Pain (2) · Diabetes Complications (2)
Pathological Conditions, Signs and Symptoms (80) · Signs and Symptoms (80) · Neurologic Manifestations (79) · Nervous System Diseases (44) · Central Nervous System Diseases (37) · Stomach Diseases (35) · Digestive System Diseases (34) · Gastrointestinal Diseases (34) · Brain Diseases (28) · Cranial Nerve Diseases (18) · Metabolic Diseases (18) · Nutritional and Metabolic Diseases (18) · Eye Diseases (15) · Glucose Metabolism Disorders (15)
N-(3-fluorophenyl)-1-((4-(((3S)-3-methyl-1-piperazinyl)methyl)phenyl)acetyl)-4-piperidinamine (5) · Metoclopramide (3) · Buspirone (2) · Constraint Induced Movement Therapy (2) · Lidocaine (2) · NG-Nitroarginine Methyl Ester (2) · Saline Solution (2) · Stroke Rehabilitation (2) · TD-5108 (2) · Tablets (2) · coenzyme Q10 (2) · relamorelin (2) · ATI 7505 (1) · Acetylcarnitine (1) · Acupuncture Therapy (1)
GlaxoSmithKline (5) · US Department of Veterans Affairs (4) · Mayo Clinic (3) · Tranzyme, Inc. (3) · VA Office of Research and Development (3) · CinDome Pharma, Inc. (2) · GemVax & Kael (2) · MetroHealth Medical Center (2) · National Institute of Neurological Disorders and Stroke (NINDS) (2) · Theravance Biopharma (2) · University of Florida (2) · Allergan (1) · Allon Therapeutics (1) · AlzProtect SAS (1) · Amgen (1)
United States (50) · Germany (9) · United Kingdom (9) · Sweden (8) · Canada (7) · Australia (6) · France (6) · Belgium (5) · Denmark (4) · Norway (3) · Poland (3) · Spain (3) · Finland (2) · Israel (2) · South Korea (2)
Sang Jae Kim (2) · Adam Boxer, M.D., PhD. (1) · Adil E Bharucha, MBBS, MD (1) · Akira Kimura, PhD (1) · Armin Curt, Prof. (1) · Arthur Prochazka (1) · Charles Burgar, MD (1) · Christian Debry, MD (1) · Christopher N Andrews, MD, MSc (1) · Claire Henchcliffe, MD DPhil (1)
PMID 32301137, PMID 12052996, PMID 14568122, PMID 14617717, PMID 17385265, PMID 17904594, PMID 17965289, PMID 19618698, PMID 19651280, PMID 19694164, PMID 19926154, PMID 20012982, PMID 20435515, PMID 21372246, PMID 21381984, PMID 21448576, PMID 21762873, PMID 23700789, PMID 23844986, PMID 23848826, PMID 24119615, PMID 24419482, PMID 24873720, PMID 25576687, PMID 26924243, PMID 27055601, PMID 27136096, PMID 27429037, PMID 27476581, PMID 28436538, PMID 28760384, PMID 29111115, PMID 29228183, PMID 29278279, PMID 29760737, PMID 32693185, PMID 33811761, PMID 34148244, PMID 34176722, PMID 34695300, PMID 35364569, PMID 35537858, PMID 35901693, PMID 36624727, PMID 36772802, PMID 37482172, PMID 37962171, PMID 38825840, PMID 39706632, PMID 40368603
U01DK073974 (2), U01DK073975 (2), U01DK073983 (2), U01DK074007 (2), U01DK074035 (2), 2014 (1), 2023 (1), K01HD069504 (1), K24HD054600 (1), P01DK068055 (1), R01DK122280 (1), U01DK073985 (1), U01DK074008 (1), U01DK112193 (1), U24DK074008 (1)